A new study reports even low levels of APOE4 can increase beta-amyloid plaques in the brain and neuronal damage in mouse models of Alzheimer's disease. However, introducing APOE2 can reduce amyloid deposits and other associated damage.
Inhibiting the NHE6 gene abolished the formation of amyloid-beta plaques in mouse models of Alzheimer's disease.
A new method of examining blood plasma allowed researchers to identify specific chemical bonds within the blood. The new technique allowed researchers to accurately distinguish between Alzheimer's disease and Lewy body dementia, thus reducing cases of misdiagnosis.
Dasatinib, an FDA-approved drug for chronic myeloid leukemia, and an experimental drug for liver cancer reduced neuroinflammation, tau phosphorylation, and amyloid secretion in cell cultures of post-mortem brain samples of those with the APOE4 Alzheimer's associated gene.
Higher levels of cortical amyloid levels linked to loneliness and an increased Alzheimer's risk, according to a new study.
15 newly discovered "hotspots" in the genome that either speed up or slow down brain aging could be new targets for the development of Alzheimer's medications and therapies for other brain disorders.
A new study provides insight into the link between ApoE4 and SirT1, an anti-aging protein found is resveratrol.
Researchers from WUSTL have identified a compound that targets APOE in mouse brains and which protects against Alzheimer's disease. The APOE4 genetic variant increases the risk of people developing Alzheimer's disease. The findings offer new possible avenues of treating the disease in humans.
Microglia that express the Alzheimer's associated APOE4 genetic variant are unable to effectively metabolize lipids. This causes lipids to build up, promoting inflammation and preventing effective neurotransmission.
Stem cell study reveals astrocytes carrying the Alzheimer's associated APOE4 gene release more cholesterol than those carrying the APOE3 gene. Findings shed light on how different versions of the APOE gene in astrocytes influence amyloid-beta production and how the oversupply of cholesterol associated with APOE4 astrocytes may promote amyloid-beta formation in Alzheimer's patients.
Researchers find brain regions associated with memory shrink as adults age. This decrease in size is more pronounced in those who later develop neurodegenerative diseases, such as Alzheimer's.
A new framework reveals Alzheimer's disease is far more complex than previously believed. Rather than being a disease where the same causes produce the same outcomes, researchers found three different models for the disease, each with its own characterizations and dynamics.
